MY204220A - Methods of treating initial episode of ttp with immunoglobulin single variable domains - Google Patents
Methods of treating initial episode of ttp with immunoglobulin single variable domainsInfo
- Publication number
- MY204220A MY204220A MYPI2020003735A MYPI2020003735A MY204220A MY 204220 A MY204220 A MY 204220A MY PI2020003735 A MYPI2020003735 A MY PI2020003735A MY PI2020003735 A MYPI2020003735 A MY PI2020003735A MY 204220 A MY204220 A MY 204220A
- Authority
- MY
- Malaysia
- Prior art keywords
- ttp
- episode
- vwf
- treating
- single variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627082P | 2018-02-06 | 2018-02-06 | |
| US201862662381P | 2018-04-25 | 2018-04-25 | |
| PCT/EP2019/052929 WO2019154867A1 (en) | 2018-02-06 | 2019-02-06 | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY204220A true MY204220A (en) | 2024-08-16 |
Family
ID=65440943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020003735A MY204220A (en) | 2018-02-06 | 2019-02-06 | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11999797B2 (https=) |
| EP (1) | EP3749696A1 (https=) |
| JP (2) | JP2021512947A (https=) |
| KR (1) | KR102929403B1 (https=) |
| CN (1) | CN111670202A (https=) |
| AU (1) | AU2019217584B2 (https=) |
| BR (1) | BR112020015991A2 (https=) |
| CA (1) | CA3089211A1 (https=) |
| IL (1) | IL276200B2 (https=) |
| MX (1) | MX2020008294A (https=) |
| MY (1) | MY204220A (https=) |
| SG (1) | SG11202006902QA (https=) |
| TW (1) | TWI889647B (https=) |
| WO (1) | WO2019154867A1 (https=) |
| ZA (1) | ZA202004370B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201805064SA (en) * | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| CA2361678A1 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| IL147920A0 (en) | 1999-08-02 | 2002-08-14 | Keygene Nv | Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2003251238A1 (en) | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
| NZ576284A (en) | 2003-01-10 | 2010-07-30 | Ablynx Nv | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| EP1656128A4 (en) | 2003-08-12 | 2007-02-28 | William M Yarbrough | SINGLE ACNE TREATMENT AND METHOD OF USE |
| US7270976B2 (en) | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| WO2006074947A2 (en) | 2005-01-14 | 2006-07-20 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2121757A2 (en) | 2007-02-21 | 2009-11-25 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2252303A2 (en) | 2008-03-21 | 2010-11-24 | Ablynx NV | Von willebrand factor specific binders and methods of use therefor |
| BRPI0919879A2 (pt) | 2008-10-29 | 2016-02-16 | Wyeth Llc | métodos para purificação de moléculas de ligação a antígeno de domínio único |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| WO2010091396A2 (en) * | 2009-02-09 | 2010-08-12 | Archemix Corp. | Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics |
| US20120321640A1 (en) | 2009-12-01 | 2012-12-20 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| DK3412305T3 (da) | 2011-06-10 | 2021-03-01 | Baxalta GmbH | Behandling af koagulationssygdom ved administration af rekombinant vwf |
| PE20141522A1 (es) * | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
-
2019
- 2019-02-06 EP EP19705466.1A patent/EP3749696A1/en active Pending
- 2019-02-06 SG SG11202006902QA patent/SG11202006902QA/en unknown
- 2019-02-06 MY MYPI2020003735A patent/MY204220A/en unknown
- 2019-02-06 AU AU2019217584A patent/AU2019217584B2/en active Active
- 2019-02-06 MX MX2020008294A patent/MX2020008294A/es unknown
- 2019-02-06 CN CN201980011292.XA patent/CN111670202A/zh active Pending
- 2019-02-06 JP JP2020563820A patent/JP2021512947A/ja active Pending
- 2019-02-06 US US16/967,514 patent/US11999797B2/en active Active
- 2019-02-06 BR BR112020015991-3A patent/BR112020015991A2/pt unknown
- 2019-02-06 KR KR1020207024118A patent/KR102929403B1/ko active Active
- 2019-02-06 IL IL276200A patent/IL276200B2/en unknown
- 2019-02-06 CA CA3089211A patent/CA3089211A1/en not_active Abandoned
- 2019-02-06 WO PCT/EP2019/052929 patent/WO2019154867A1/en not_active Ceased
- 2019-02-11 TW TW108104485A patent/TWI889647B/zh active
-
2020
- 2020-07-16 ZA ZA2020/04370A patent/ZA202004370B/en unknown
-
2023
- 2023-10-04 JP JP2023172414A patent/JP2024001135A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202004370B (en) | 2024-08-28 |
| US20210221912A1 (en) | 2021-07-22 |
| KR20200118444A (ko) | 2020-10-15 |
| BR112020015991A2 (pt) | 2020-12-15 |
| JP2021512947A (ja) | 2021-05-20 |
| TW201945030A (zh) | 2019-12-01 |
| WO2019154867A1 (en) | 2019-08-15 |
| RU2020129228A (ru) | 2022-03-09 |
| CA3089211A1 (en) | 2019-08-15 |
| CN111670202A (zh) | 2020-09-15 |
| SG11202006902QA (en) | 2020-08-28 |
| IL276200B1 (en) | 2024-09-01 |
| MX2020008294A (es) | 2020-11-18 |
| TWI889647B (zh) | 2025-07-11 |
| JP2024001135A (ja) | 2024-01-09 |
| US11999797B2 (en) | 2024-06-04 |
| IL276200B2 (en) | 2025-01-01 |
| EP3749696A1 (en) | 2020-12-16 |
| KR102929403B1 (ko) | 2026-02-24 |
| AU2019217584B2 (en) | 2025-08-14 |
| IL276200A (en) | 2020-09-30 |
| AU2019217584A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Long et al. | Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines | |
| Abcouwer | Müller cell–microglia cross talk drives neuroinflammation in diabetic retinopathy | |
| Park et al. | Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study | |
| Rezaei et al. | In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial | |
| Guo et al. | Passive transfer autoimmunity in a mouse model of complex regional pain syndrome | |
| ZA202004370B (en) | Methods of treating initial episode of ttp with immunoglobulin single variable domains | |
| HRP20170130T1 (hr) | Načini liječenja dijabetesa antagonistima gena dll4 | |
| GEP20267851B (en) | Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders | |
| Onwuemene et al. | Heparin-induced thrombocytopenia: research and clinical updates | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| Mayer et al. | New aspects on the efficacy of high‐dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia | |
| Lampropoulos et al. | Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: A real-world study | |
| Cannon et al. | Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience | |
| Xu et al. | Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis | |
| Warkentin | Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)–bridging the River Coumarin | |
| Quinn et al. | Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion | |
| AR114958A1 (es) | Métodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina | |
| Malavera et al. | Prognostic significance of early pyrexia in acute intracerebral haemorrhage: the INTERACT2 study | |
| Fragoso et al. | Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab | |
| Oberle et al. | Precision medicine in asthma: the role of bronchial thermoplasty | |
| de Takats | Nervous regulation of clotting mechanism | |
| Nguyen et al. | Extensive purpura as presenting sign of parvovirus B19 infection in a patient with paroxysmal nocturnal hemoglobinuria | |
| Paulson et al. | Medical aspects of vagotomy for peptic ulcer, including observations on the clinical value of the insulin test and on post-operative criteria for the completeness of bilateral gastric vagus section | |
| Ghanima et al. | Immune thrombocytopenia: Modern management, knowledge gaps, and future perspectives | |
| Cooper et al. | PB2636: VAYHIT1: a multicenter, randomized, double-blind, phase iii trial of IANALUMAB versus placebo in addition to FIRST-line corticosteroids in patients with primary immune thrombocytopenia (ITP) |